Global Regulatory Knowledge Hub

Need a CDSCO consultant for medical devices in India? See licence routes, timelines, costs and 2026 rule changes, and avoid the errors that stall approvals.

Need a medical device regulatory consultant in India? Learn what they do, CDSCO steps, 2026 rule changes, costs, and how to pick the right partner.

Learn how to register a medical device in India: CDSCO classes, MD forms, documents, fees and timelines explained step by step for 2026.

EUDAMED's first four modules are now mandatory. Review the registration, UDI/device, certificate and market-surveillance implications manufacturers should address now.

FDA has moved away from QSIT to the QMSR-aligned inspection process. Learn what investigators may review and how to strengthen inspection readiness.

A practical regulatory perspective for manufacturers developing AI-enabled medical devices and medical software for the European market.

A practical regulatory perspective on the issues that can delay CE marking and EU market entry under Regulation (EU) 2017/745.

What the latest MDR amendment (G.S.R. 744(E)) means for medical device manufacturers, EU companies and Indian importers.

Why auditors look for lifecycle traceability and how to turn static technical files into defensible regulatory evidence during inspections.

Plan EU medical software qualification, classification, clinical evidence, and release controls around a clearly defined intended purpose.

Assess FDA QMSR readiness through connected product records, supplier controls, complaints, and management decisions rather than a document count.

Connect software incidents, dependency updates, and clinical feedback to risk assessment, change control, and verified release decisions.

Define a workable PRRC arrangement with appropriate qualifications, access to evidence, escalation routes, and clear manufacturer responsibilities.

Organise medical-device QMS documentation around process ownership, controlled records, traceability, and reliable retrieval.

Evaluate technical, biological, and clinical equivalence, data access, and evidence gaps before relying on another device's clinical data.

Build a usable GSPR matrix linking applicable requirements to methods, controlled evidence, product configurations, and unresolved gaps.

Plan an Indian medical-device manufacturing application around classification, site scope, product evidence, and consistent licence documentation.

Investigate FDA classification, product codes, and evidence requirements before assuming that a device needs a 510(k) or a PMA.

Use GSPRs during device development to define measurable design inputs, evidence dependencies, and review gates before testing begins.

Plan cardiovascular-device evidence across design performance, patient contact, clinical benefit, and follow-up without assuming one route fits all products.

Organise a medical-device software lifecycle around traceable requirements, risk controls, verification, third-party software, and release records.

Assess remote-monitoring systems through their measurement claims, alerts, data flow, home-use conditions, and clinical responsibilities.

Prepare Class D IVD verification with clear configurations, performance evidence, batch records, and notified-body or reference-laboratory interfaces.

Plan dental-scanner evidence for intended use, scan accuracy, software processing, reprocessing, and downstream digital workflows.

Assess borderline products using intended purpose, mode of action, claims, and jurisdiction-specific reasoning before selecting a device class.

Prepare an MDR technical file with consistent scope, claim-to-evidence links, controlled revisions, and traceable responses to review questions.

Address 510(k) obstacles by distinguishing pathway, intended-use, performance-evidence, and submission-consistency problems.

Build CAPA records around problem definition, investigation, cause-based actions, effectiveness measures, and a justified closure decision.

Separate reusable product evidence from market-specific classification, representation, and submission needs in a global regulatory plan.

Assess IVDR legacy-device transition eligibility, application milestones, change restrictions, and evidence before relying on extended dates.

Plan biological evaluation using finished-device contact, materials, processing, available evidence, and current standards-recognition requirements.

Create a product-specific register linking device rules, software, electrical safety, biological evaluation, and other applicable obligations.

Assess 510(k) readiness through intended use, predicate strategy, completed evidence, configuration control, and capacity to answer review questions.

Plan usability evaluations around representative users, critical tasks, realistic conditions, observations, and justified interpretation.

Understand predicate relevance, final versus draft guidance, and the limited scope of FDA's Safety and Performance Based Pathway.

Integrate human factors into early device design through user research, task analysis, formative evaluation, and traceable design decisions.

Prepare an Indian medical-device registration strategy using product classification, applicant roles, manufacturing or import scope, and current rules.

Sequence EU MDR qualification, classification, evidence, conformity assessment, declaration, and ongoing obligations in a practical project plan.

Define medical software functions, assess FDA regulatory treatment, and connect classification and submission evidence to the intended use.

Prepare a focused FDA Pre-Submission with a defined device, evidence context, proposed approach, and questions tied to development decisions.

Choose a notified body by confirming designation scope, product fit, assessment requirements, and realistic readiness rather than quoted timing alone.

QMSR is now effective. Understand the key changes, ISO 13485 alignment, record expectations and practical actions manufacturers should take for ongoing FDA compliance.

EUDAMED’s first four modules are now mandatory. Review the registration, UDI/device, certificate and market-surveillance implications manufacturers should address now.

FDA has moved away from QSIT to the QMSR-aligned inspection process. Learn what investigators may review and how to strengthen inspection readiness.